Analyst Ratings For Cytori Therapeutics Inc (NASDAQ:CYTX)
Today, Maxim Group lowered its price target on Cytori Therapeutics Inc (NASDAQ:CYTX) to $3.00 per share.
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Cytori Therapeutics Inc (NASDAQ:CYTX) is Buy with a consensus target price of $8.50 per share, a potential 1,131.88% upside.
Some recent analyst ratings include
- 7/11/2018-HC Wainwright Reiterated Rating of Buy.
- 3/9/2018-B. Riley Upgrade from a “Neutral ” rating to a ” Buy” rating.
- 2/22/2018-Laidlaw Reiterated Rating of Buy .
Recent Insider Trading Activity For Cytori Therapeutics Inc (NASDAQ:CYTX)
Cytori Therapeutics Inc (NASDAQ:CYTX) has insider ownership of 0.80% and institutional ownership of 71.14%.
- On 2/13/2018 Ag Postfinance, Major Shareholder, sold 286,982 with an average share price of $0.31 per share and the total transaction amounting to $88,964.42.
- On 2/9/2018 Ag Postfinance, Major Shareholder, sold 236,155 with an average share price of $0.34 per share and the total transaction amounting to $80,292.70.
- On 1/11/2018 Bank Sa Swissquote, Major Shareholder, sold 72,630 with an average share price of $0.34 per share and the total transaction amounting to $24,694.20.
- On 1/9/2018 Bank Sa Swissquote, Major Shareholder, sold 100,000 with an average share price of $0.38 per share and the total transaction amounting to $38,000.00.
- On 8/10/2016 John David Harris, VP, bought 2,500 with an average share price of $2.03 per share and the total transaction amounting to $5,075.00.
- On 6/14/2016 Gail K Naughton, Director, bought 1,000 with an average share price of $2.10 per share and the total transaction amounting to $2,100.00.
- On 5/13/2016 John David Harris, VP, bought 2,000 with an average share price of $2.71 per share and the total transaction amounting to $5,420.00.
About Cytori Therapeutics Inc (NASDAQ:CYTX)
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Recent Trading Activity for Cytori Therapeutics Inc (NASDAQ:CYTX)
Shares of Cytori Therapeutics Inc closed the previous trading session at 0,71 −0,0099 1,38 % with shares trading hands.